A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
A phase 2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Fujifilm Pharmaceuticals U.S.A., Inc., active and no longer recruiting.
Overview
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT05318573 by Fujifilm Pharmaceuticals U.S.A., Inc., with 120 participants planned, started 2022-06-01 and due to reach its primary completion in 2029-05. Interventions recorded: Pembrolizumab, FF-10832. Conditions listed: Advanced Urothelial Carcinoma, Advanced Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Setting
A Phase 2a Study With Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Phase
Phase 2
Sponsor
Fujifilm Pharmaceuticals U.S.A., Inc.
Registry
Enrolled
120